Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   D-213-24 MTA Custom (Custom)
AR Bank # 1274 Acinetobacter baumannii
Study ID: ACI-46

Biosample Accession #: SAMN35995979

   

Collection Year: 2019
Location: USA
Source: Peritoneal
MLST: ST2(Pasteur), ST281(Oxford)


Panel:  Acinetobacter baumannii (ACI)  |  Acinetobacter Add-ons (Custom)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin >64R
Ampicillin/sulbactam 1>32R
Cefepime >32R
Cefotaxime >64R
Ceftazidime >128R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 41I
Gentamicin >16R
Imipenem >64R
Imipenem+chelators 2>32---
Levofloxacin 8R
Meropenem >8R
Minocycline <=4S
Piperacillin/tazobactam 1>128R
Tetracycline >32R
Tigecycline 31---
Tobramycin >16R
Trimethoprim/sulfamethoxazole 1>8R
MICs obtained by broth microdilution. Modal MIC is reported
S – I –R Interpretation (INT) derived from CLSI 2024 M100 S34
1 Reflects MIC of first component
2 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
3 Based on FDA break points
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(6')-Ib-AKT, aadA1, ant(3")-IIa, aph(3')-Ia, aph(6)-Id, armA, strA
Beta-lactam ADC-30, NDM-1, OXA-23, OXA-66
Bleomycin ble-MBL
Efflux pumps/Other ADEC, qacEdelta1
Fosfomycin ABAF
Macrolide-Lincosamide-Streptogramin mph(E), msr(E)
Phenicols/Bicyclomycins catB8, cmlA5
Rifampicin ARR-2
Sulfonamides sul1, sul2
Tetracyclines tet(B)
 
Disclaimer:
The resistance mechanisms listed were identified by analysis of whole genome sequence using the ResFinder database (last updated June 2, 2016 and accessed on October 25, 2016). This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of the ResFinder database or other antimicrobial resistance gene databases. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2 °C for 20-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

Disclaimer:
This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
06/27/23Sequence Accession # changed: from '---' to 'SAMN35995979'
05/05/23Isolate Status changed: from 'Pending' to 'Active'
05/02/23MIC was updated with a new value for Imipenem+chelators: from '---' to '>32'
05/02/23Drug was added: Imipenem+chelators
Top of Page
TOP